IL17A and autoimmune disease: Since IFN-γ and IL-17 contribute in the genesis of autoimmune diseases (75, 76), the capacity of ES L1-induced tolerogenic DCs to reduce the production of these cytokines could favor the potential applicability of these DCs in the treatment of autoimmune diseases.